Impaired Renal Function on Cholesterol Efflux Capacity, HDL Particle Number, and Cardiovascular Events

Chindhy, Shahzad; Joshi, Parag H.; Khera, Amit; Ayers, Colby; Hedayati, S. Susan; Rohatgi, Anand

doi:10.1016/j.jacc.2018.05.043

Cited by 21 publications

(19 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, the HDL cholesterol efflux capacity of apoB-depleted serum was not associated with cardiovascular outcome in the CARE FOR HOMe study, a prospective cohort study with pre-dialysis CKD patients [19,116] and in the German Diabetes Dialysis Study (4D Study) [21]. In the Dallas Heart Study , a population-based cohort of participants without widespread cardiovascular disease, a higher cholesterol efflux capacity was paradoxically even associated with an increase in cardiovascular mortality among participants with a baseline eGFR < 60 mL/min/1.73 m 2 [20]. Interestingly, one study among renal allograft recipients reported that cholesterol efflux capacity strongly predicted kidney graft failure independent of plasma HDL-C levels [131].…”

Section: Hdl-cholesterol Efflux Capacity In Ckd Patientsmentioning

confidence: 97%

“…In healthy subjects with intact renal function, the ability of HDL to promote cholesterol efflux is a predictor of cardiovascular risk, even independently of HDL-C levels [17,18]. However, despite the dramatically increased cardiovascular risk in CKD patients, neither HDL-C levels nor HDL cholesterol efflux capacity associate with prevalent ASCVD or predict future cardiovascular events in these individuals [3,[19][20][21].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Current Understanding of the Relationship of HDL Composition, Structure and Function to Their Cardioprotective Properties in Chronic Kidney Disease

et al. 2020

View full text Add to dashboard Cite

In the general population, the ability of high-density lipoproteins (HDLs) to promote cholesterol efflux is a predictor of cardiovascular events, independently of HDL cholesterol levels. Although patients with chronic kidney disease (CKD) have a high burden of cardiovascular morbidity and mortality, neither serum levels of HDL cholesterol, nor cholesterol efflux capacity associate with cardiovascular events. Important for the following discussion on the role of HDL in CKD is the notion that traditional atherosclerotic cardiovascular risk factors only partially account for this increased incidence of cardiovascular disease in CKD. As a potential explanation, across the spectrum of cardiovascular disease, the relative contribution of atherosclerotic cardiovascular disease becomes less important with advanced CKD. Impaired renal function directly affects the metabolism, composition and functionality of HDL particles. HDLs themselves are a heterogeneous population of particles with distinct sizes and protein composition, all of them affecting the functionality of HDL. Therefore, a more specific approach investigating the functional and compositional features of HDL subclasses might be a valuable strategy to decipher the potential link between HDL, cardiovascular disease and CKD. This review summarizes the current understanding of the relationship of HDL composition, metabolism and function to their cardio-protective properties in CKD, with a focus on CKD-induced changes in the HDL proteome and reverse cholesterol transport capacity. We also will highlight the gaps in the current knowledge regarding important aspects of HDL biology.

show abstract

Section: Hdl-cholesterol Efflux Capacity In Ckd Patientsmentioning

confidence: 97%

Section: Introductionmentioning

confidence: 99%

Current Understanding of the Relationship of HDL Composition, Structure and Function to Their Cardioprotective Properties in Chronic Kidney Disease

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In several clinical trials, HDL CEC predicted future CV events [ 58 , 59 , 72 , 73 , 74 , 75 , 76 , 77 , 78 ] so it has been defined as a good marker of CVD risk in a recent roundtable discussion [ 10 ] (see Table 2 for the main results of longitudinal studies). The predictive power of HDL CEC on ACS incidence has also been recently evaluated in a prospective setting on a subset of high CV risk participants of the PREDIMED study.…”

Section: Hdl Cec Atherosclerosis and Cardiovascular Riskmentioning

confidence: 99%

High Density Lipoprotein Cholesterol Efflux Capacity and Atherosclerosis in Cardiovascular Disease: Pathophysiological Aspects and Pharmacological Perspectives

Adorni

Ronda

Bernini

et al. 2021

Cells

View full text Add to dashboard Cite

Over the years, the relationship between high-density lipoprotein (HDL) and atherosclerosis, initially highlighted by the Framingham study, has been revealed to be extremely complex, due to the multiple HDL functions involved in atheroprotection. Among them, HDL cholesterol efflux capacity (CEC), the ability of HDL to promote cell cholesterol efflux from cells, has emerged as a better predictor of cardiovascular (CV) risk compared to merely plasma HDL-cholesterol (HDL-C) levels. HDL CEC is impaired in many genetic and pathological conditions associated to high CV risk such as dyslipidemia, chronic kidney disease, diabetes, inflammatory and autoimmune diseases, endocrine disorders, etc. The present review describes the current knowledge on HDL CEC modifications in these conditions, focusing on the most recent human studies and on genetic and pathophysiologic aspects. In addition, the most relevant strategies possibly modulating HDL CEC, including lifestyle modifications, as well as nutraceutical and pharmacological interventions, will be discussed. The objective of this review is to help understanding whether, from the current evidence, HDL CEC may be considered as a valid biomarker of CV risk and a potential pharmacological target for novel therapeutic approaches.

show abstract

“…The 20 articles reported on 10 different longitudinal cohorts [14][15][16][17][18][19][20][21][22][23][24] and 3 case controls nested within cohorts [25][26][27], and 7 cross-sectional or case control studies [14,[28][29][30][31][32][33]. Six studies [15,16,18,21,23,24] reported on the risk of death of all-cause. Two papers analyzed all-cause mortality within a combined endpoint, therefore we did not include them in the meta-analysis focusing on allcause mortality [18,26].…”

Section: Cholesterol Efflux Capacity (Cec)mentioning

confidence: 99%

“…In another study [33], a β-coefficient was provided without a standard error or confidence interval. Three articles analyzed the relationship between CEC and the risk of CVD in the same sample from the Dallas Heart Study [19][20][21] so we only include in the meta-analysis estimates with the longest followup [20]. In 18 articles, the authors included HDL-C as a covariate [14][15][16][17][18][19][20][21][22][23][24][25][27][28][29][30][31]33].…”

Section: Cholesterol Efflux Capacity (Cec)mentioning

confidence: 99%

High density lipoprotein functionality and cardiovascular events and mortality: A systematic review and meta-analysis

et al. 2020

View full text Add to dashboard Cite

First meta-analysis on the association between a wide range of HDL functions and the risk of cardiovascular disease and all-cause mortality • Higher cholesterol efflux and antioxidant/anti-inflammatory capacities promoted by HDL are associated with lower cardiovascular disease risk.• Higher cholesterol efflux capacity and antioxidant activity are associated with lower risk of all-cause mortality • Heterogeneity between studies and evidence of publication bias warrants caution and highlights the need for larger prospective studies

show abstract

Impaired Renal Function on Cholesterol Efflux Capacity, HDL Particle Number, and Cardiovascular Events

Cited by 21 publications

References 5 publications

Current Understanding of the Relationship of HDL Composition, Structure and Function to Their Cardioprotective Properties in Chronic Kidney Disease

Current Understanding of the Relationship of HDL Composition, Structure and Function to Their Cardioprotective Properties in Chronic Kidney Disease

High Density Lipoprotein Cholesterol Efflux Capacity and Atherosclerosis in Cardiovascular Disease: Pathophysiological Aspects and Pharmacological Perspectives

High density lipoprotein functionality and cardiovascular events and mortality: A systematic review and meta-analysis

Contact Info

Product

Resources

About